Cargando…

Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies

BACKGROUND: In an era of scarce resources, policy makers, neurologists and other stakeholders need to be aware of the economic burden of multiple sclerosis and the cost-effectiveness of disease-modifying therapies. The aim of this article is to provide a mini-review of these health economic facets o...

Descripción completa

Detalles Bibliográficos
Autor principal:	Simoens, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631775/ https://www.ncbi.nlm.nih.gov/pubmed/36341111 http://dx.doi.org/10.3389/fneur.2022.1015256

Ejemplares similares

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
por: Simone, Isabella Laura, et al.
Publicado: (2021)

The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses
por: Claflin, Suzi B., et al.
Publicado: (2019)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy
por: Melnikov, Mikhail, et al.
Publicado: (2022)

Does the inclusion of societal costs change the economic evaluations recommendations? A systematic review for multiple sclerosis disease
por: Rodríguez-Sánchez, B., et al.
Publicado: (2022)

Economic burden of multimorbidity among older adults: impact on healthcare and societal costs
por: Picco, Louisa, et al.
Publicado: (2016)

Changes in John Cunningham Virus Index in Multiple Sclerosis Patients Treated with Different Disease-Modifying Therapies
por: Sgarlata, Eleonora, et al.
Publicado: (2022)

Multiple sclerosis and exercise—A disease-modifying intervention of mice or men?
por: Martin, Sarah-Jane, et al.
Publicado: (2023)

Assessment of the Burden of Multiple Sclerosis Patients' Caregivers in Saudi Arabia
por: Algahtani, Hussein, et al.
Publicado: (2020)

A Framework for Estimating the Burden of Chronic Diseases: Design and Application in the Context of Multiple Sclerosis
por: Kaufmann, Marco, et al.
Publicado: (2019)

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies
por: Bridge, Francesca, et al.
Publicado: (2023)

The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review
por: Kania, Karolina, et al.
Publicado: (2023)

The societal cost of Huntington's disease: are we underestimating the burden?
por: Jones, C., et al.
Publicado: (2016)

Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review
por: Capone, Fioravante, et al.
Publicado: (2022)

Perspectives for Managed Care Organizations on the Burden of Multiple Sclerosis and the Cost-Benefits of Disease-Modifying Therapies
por: Owens, Gary M., et al.
Publicado: (2013)

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
por: Vollmer, Brandi L., et al.
Publicado: (2022)

Societal costs and burden of otitis media in Portugal
por: Speets, Anouk, et al.
Publicado: (2011)

Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study
por: Al-Sakran, Lina, et al.
Publicado: (2019)

Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective
por: Chevalier, Julie, et al.
Publicado: (2016)

The economic burden of cervical cancer in Eswatini: Societal perspective
por: Ngcamphalala, Cebisile, et al.
Publicado: (2021)

Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study
por: Arroyo, Rafael, et al.
Publicado: (2017)

Guidance for Demonstrating the Societal Value of new Antibiotics
por: Simoens, Steven, et al.
Publicado: (2021)

The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs
por: Bebo, Bruce, et al.
Publicado: (2022)

The economic and societal burden associated with adolescent idiopathic scoliosis: A burden-of-disease study protocol
por: Hoelen, Thomáy-Claire Ayala, et al.
Publicado: (2023)

60/30: 60% of the Morbidity-Associated Multiple Sclerosis Disease Burden Comes From the 30% of Persons With Higher Impairments
por: Kaufmann, Marco, et al.
Publicado: (2020)

Health Economic Assessment: Cost-Effectiveness Thresholds and Other Decision Criteria
por: Simoens, Steven
Publicado: (2010)

The Economic Burden of Cancer in Canada from a Societal Perspective
por: Garaszczuk, Roxanne, et al.
Publicado: (2022)

Health economics of disease-modifying therapy for multiple sclerosis in the United States
por: Hartung, Daniel M.
Publicado: (2021)

The Economic impact of ME/CFS: Individual and societal costs
por: Jason, Leonard A, et al.
Publicado: (2008)

The societal cost of modifiable risk factors in Singapore
por: Tan, Vanessa, et al.
Publicado: (2023)

Large-scale cross-sectional online survey on patient-neurologist communication, burden of disease assessment and disease monitoring in people with multiple sclerosis
por: Christ, Monika, et al.
Publicado: (2023)

Predictors for Therapy Response to Intrathecal Corticosteroid Therapy in Multiple Sclerosis
por: Vohl, Katja, et al.
Publicado: (2019)

The societal economic burden of autosomal dominant polycystic kidney disease in the United States
por: Cloutier, Martin, et al.
Publicado: (2020)

The personal, societal, and economic burden of schizophrenia in the People’s Republic of China: implications for antipsychotic therapy
por: Montgomery, William, et al.
Publicado: (2013)

Economic costs of hospitalized diarrheal disease in Bangladesh: a societal perspective
por: Sarker, Abdur Razzaque, et al.
Publicado: (2018)

Impact of disease-modifying therapies on MRI and neurocognitive outcomes in relapsing–remitting multiple sclerosis: a protocol for a systematic review and network meta-analysis
por: Lees, Samuel, et al.
Publicado: (2021)

Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
por: Jayaraman, Sundararajan, et al.
Publicado: (2022)

The Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis by Disease Severity
por: Hendin, Barry, et al.
Publicado: (2023)

Burden and cost of multiple sclerosis in Brazil
por: Kobelt, Gisela, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_akvbe6431h0g65pe91qpkb56bj